MTX-211
/ Mekanistic Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 25, 2024
ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells.
(PubMed, Int J Mol Sci)
- "In summary, our findings indicate that MTX-211 acts as a substrate for ABCG2, underscoring the involvement of ABCG2 in the emergence of resistance to MTX-211. This finding carries clinical implications and merits further exploration."
Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • ABCG2 • EGFR • KRAS
April 28, 2023
MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer.
(PubMed, Int J Mol Sci)
- "This study provided evidence that MTX-211 effectively inhibited BLCA cell proliferation via depleting GSH levels through Keap1/NRF2/GCLM signaling pathway. Thus, MTX-211 could be a promising therapeutic agent for cancer."
Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • Urothelial Cancer • KEAP1
1 to 2
Of
2
Go to page
1